文献速递脑血管病

未确定来源栓塞性卒中抗血小板或抗凝治疗的多中心队列结局

Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation: A Multicenter Cohort Study.
PubMed 文献 · Neurology · 2025-07-03

该多中心回顾性队列研究纳入2015至2024年27个中心的2328例ESUS患者,比较抗血小板与抗凝治疗后的复合结局。调整后分析显示抗凝未降低主要结局风险,但左心室损伤亚组抗凝可能获益,需未来试验验证。

要点

  • ESUS患者中抗凝治疗较抗血小板未降低复发卒中、大出血或死亡复合风险。
  • 左心室损伤亚组中抗凝与主要结局风险降低相关,交互作用显著。
  • 真实世界数据验证随机试验结果,抗凝在ESUS中无净获益。

核心结论

  • 在ESUS患者中,抗凝治疗相比抗血小板治疗未降低复发卒中、大出血或死亡的复合风险。
  • 左心室损伤患者中抗凝可能降低主要结局风险,但证据受抗凝治疗人数少限制。

研究设计与样本

  • 多中心回顾性观察性队列研究,纳入27个中心2015至2024年连续成人急性缺血性卒中ESUS患者。
  • 共纳入2328例患者,其中230例接受抗凝治疗,中位年龄65岁,50%为女性,中位NIHSS评分4分。

主要发现

  • 调整后Cox模型显示抗凝 vs 抗血小板的主要结局aHR为1.00(95%CI 0.69-1.45)。
  • IPTW调整模型aHR为1.15(95%CI 0.79-1.66),10:1倾向评分匹配模型aHR为1.00(95%CI 0.70-1.44)。
  • 左心室损伤患者中抗凝 vs 抗血小板的主要结局aHR为0.35(95%CI 0.16-0.77),交互作用p<0.01。
  • 左心室损伤患者中复发缺血性卒中aHR为0.22(95%CI 0.05-1.08),交互作用p=0.04。

临床怎么用

  • ESUS患者不应常规使用抗凝替代抗血小板以预防复发卒中、出血或死亡。
  • 对合并左心室损伤的ESUS患者,可个体化考虑抗凝治疗,但需权衡证据局限性。

局限性

  • 抗凝治疗患者数量较少(n=230),可能限制亚组分析效能。
  • 回顾性观察性设计存在残余混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Embolic stroke of undetermined source (ESUS) can be attributed to a variety of potential embolic sources, with differential response to anticoagulation. METHODS: A multicenter, retrospective observational cohort study (27 sites) of consecutive adult patients with acute ischemic stroke due to ESUS (admitted 2015-2024) was conducted. The aim was to compare outcomes after antiplatelet(s) vs anticoagulant (±antiplatelet) treatment in patients with ESUS across potential embolic sources. The time from admission to the primary composite outcome of recurrent stroke, major bleeding, or death was assessed using adjusted Cox proportional hazard regression (clustered by site) and propensity score (PS) matching with (1) inverse probability of treatment weighting (IPTW) and (2) 10:1 nearest-neighbor matching with replacement, adjusting for age, stroke severity, and potential embolic sources (e.g., left ventricular injury and patent foramen ovale). Recurrent stroke, major bleeding, and death were also assessed as secondary outcomes, with stratification by potential embolic sources. RESULTS: Of the 2,328 included patients (n = 230 treated with anticoagulation), the median age was 65 years (interquartile range [IQR] 54-75), 50% were female, and the median NIH Stroke Scale score was 4 (IQR 2-11). Compared with patients treated using antiplatelet(s) therapies, those treated with anticoagulants were not at a lower risk of the primary outcome in the adjusted Cox model (adjusted hazard ratio [aHR] 1.00, 95% CI 0.69-1.45), adjusted IPTW regression model (aHR 1.15, 95% CI 0.79-1.66), or 10:1 PS-matched regression model (aHR 1.00, 95% CI 0.70-1.44). In patients with left ventricular injury, anticoagulation was associated with a lower rate of the primary outcome (aHR 0.35, 95% CI 0.16-0.77; p-interaction <0.01) and trended toward a lower rate of recurrent ischemic stroke (aHR 0.22, 95% CI 0.05-1.08; p-interaction = 0.04) when compared with patients treated with antiplatelet(s). DISCUSSION: These real-world data validate randomized trial results in ESUS, which reported no net benefit of anticoagulation over antiplatelet therapy. These data suggest possible benefit of anticoagulation in patients with left ventricular injury, as in previous cohort studies, although the findings are limited by the small number of patients treated with anticoagulation. Future trials should evaluate treatment differences in this subgroup. TRIAL REGISTRATION INFORMATION: Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence; registration ID: NCT06398366. Registered on May 3, 2024. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that in patients with ESUS, anticoagulation was not superior to antiplatelet therapy in reducing the risk of recurrent stroke, bleeding, or death.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Siegler JE, Goicoechea EB, Penckofer M, et al. Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation: A Multicenter Cohort Study. Neurology. 2025. PMID: 40609061. doi:10.1212/WNL.0000000000213876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。